GLP-1 plus TRT to Preserve Muscle in Men with Obesity

Estimated reading time: 9 minutes

Key Takeaways

GLP-1 therapies reduce weight largely from fat; 15–40% of loss can be lean mass, which isn’t necessarily pathologic sarcopenia.
Strength and muscle quality may improve despite small DXA‑measured lean mass declines; DXA can overestimate true muscle loss.
GLP-1RAs may modestly raise total testosterone in obese or functionally hypogonadal men while preserving LH/FSH, a fertility advantage over TRT.
TRT can improve symptoms and lean mass in confirmed hypogonadism; TRAVERSE data are reassuring, but FDA cautions and monitoring remain essential.
Combining GLP-1RAs with TRT may help select men with functional hypogonadism, but high‑quality trials are lacking; resistance training and adequate protein remain foundational.

Why GLP-1 Weight Loss Can Trim Lean Mass—And Why That’s Not Always Sarcopenia
GLP-1s and the Male Hormone Axis: A New Piece of the Puzzle
Where TRT Fits—Benefits, Limits, and Safety in 2025–2026
The Case for a Combined Strategy in Functional Hypogonadism
Practical Ways to Protect Muscle on GLP‑1s (With or Without TRT)
Who Might Consider GLP‑1 + TRT—and Who Shouldn’t
Evidence Gaps and What to Watch Next
What This Means for Patients and Clinics
Conclusion

Why GLP-1 Weight Loss Can Trim Lean Mass—And Why That’s Not Always Sarcopenia

GLP-1RAs such as semaglutide and tirzepatide drive clinically meaningful weight loss. Across trials, roughly a quarter to a third of that weight can be categorized as lean tissue, with ranges from 15% to 40% depending on age, baseline body composition, and measurement tools. This has prompted concern about “GLP-1–induced sarcopenia.”

The dominant change remains fat loss; smaller decrements in lean mass are common across all effective weight-loss interventions.
DXA, a standard tool in trials, counts water, organ mass, and intramuscular fat within “lean mass,” tending to overstate actual skeletal muscle loss.
MRI and functional measures tell a fuller story. Studies report reduced intramuscular fat (myosteatosis) and improved handgrip strength in some cohorts, even when DXA signals a lean mass drop—suggesting muscle quality may improve as the metabolic milieu normalizes.

Bottom line: lean mass declines during GLP-1 therapy are often a physiologic part of weight loss, not necessarily pathologic sarcopenia. Still, the risk likely rises with age, frailty, pre-existing sarcopenia, or inactivity—so prevention strategies matter.

GLP-1s and the Male Hormone Axis: A New Piece of the Puzzle

A 2026 systematic review of studies in men reported that GLP-1RAs:

Increased total testosterone, especially in obese or functionally hypogonadal men.
Preserved or raised LH/FSH levels (contrasting with TRT, which suppresses gonadotropins).
Improved semen parameters in some obese/hypogonadal groups, with little change in otherwise healthy men.

Interpretation for practice:

GLP-1RAs may improve the endocrine environment indirectly via weight loss and insulin sensitivity, and possibly through direct testicular effects.
For men trying to conceive or for whom fertility preservation is crucial, GLP-1RA–led weight loss can be a fertility-sparing way to improve testosterone status before considering TRT.

Where TRT Fits—Benefits, Limits, and Safety in 2025–2026

TRT can improve sexual function, energy, and body composition in men with confirmed hypogonadism. Updated evidence from the TRAVERSE trial showed non-inferiority versus placebo for major adverse cardiovascular events with a commonly used transdermal formulation, offering reassurance in appropriately selected men. That said:

FDA labeling continues to warn about possible increased cardiovascular risk with testosterone in aging men treated for age-related, rather than pathologic, hypogonadism.
Hematocrit can rise on TRT, increasing thrombotic risk if not monitored and managed.
PSA and prostate health require ongoing surveillance.
Modest blood pressure increases have been noted in ambulatory monitoring studies.

Implications for a GLP-1 + TRT approach:

TRT is not a weight-loss drug—but in hypogonadal men, it can support lean mass, physical function, and symptom relief as weight comes off with GLP-1 therapy.
The cardiometabolic gains from GLP-1s (glycemia, weight, visceral fat, liver fat) may complement the anabolic and symptomatic benefits of TRT.
The combined strategy should be reserved for men who meet criteria for TRT, rather than used broadly as a muscle-sparing hack.

The Case for a Combined Strategy in Functional Hypogonadism

Functional hypogonadism—low testosterone linked to obesity and metabolic disease rather than irreversible testicular or pituitary pathology—sits at the crossroads of weight, hormones, and muscle. Here’s the theoretical synergy:

GLP-1RAs: drive fat loss, improve insulin resistance and inflammation, reduce myosteatosis, and may nudge total testosterone upward while keeping LH/FSH intact.
TRT: addresses hypogonadal symptoms and can improve lean mass and strength when true deficiency is documented.

Recent reviews suggest integrating GLP-1 therapy with TRT for select men with functional hypogonadism could accelerate metabolic recovery while protecting muscle. But robust randomized trials of the combination are still not available. One active trial (SEMAT) is comparing semaglutide and injectable testosterone head-to-head in men with obesity, type 2 diabetes, and functional hypogonadism; its findings will help clarify where each therapy excels and for whom. See the active study listing: SEMAT Trial: Semaglutide vs. TRT in Functional Hypogonadism.

For now, a patient-centered decision requires:

Confirming the diagnosis and cause of hypogonadism.
Prioritizing GLP-1RAs and lifestyle for weight-first metabolic improvement when fertility is a priority.
Considering TRT when symptoms and labs support it—and when expected benefits outweigh individualized risks.

Practical Ways to Protect Muscle on GLP‑1s (With or Without TRT)

Medication choices are only part of the equation. The most consistent protectors of muscle during weight loss remain training and nutrition.

Resistance training anchors the plan.
- Prioritize multi-joint movements across the week.
- If new to lifting, start conservatively and progress gradually; even two short weekly sessions can help maintain strength in early weight loss phases.
Protein supports lean tissue retention.
- Higher intakes are commonly recommended in active weight loss. The exact target should be individualized; many athletes and clinicians use thresholds around at least 1.2–1.6 g/kg/day, but needs vary with age, training volume, and comorbidities.
- Distribute protein across meals to support muscle protein synthesis.
Keep moving on non-lifting days.
- Regular walking or low-impact cardio supports energy balance and metabolic health without excessive recovery cost.
Manage the pace of weight loss.
- Rapid weight loss elevates the risk of disproportionate lean mass loss. A steady, sustainable rate is generally friendlier to muscle and performance.
Address sleep, alcohol, and medications that can affect muscle.
- Poor sleep and excess alcohol are catabolic, and certain medications can influence muscle metabolism or hydration status.

Investigational approaches (not standard of care) include ActRII pathway antagonists (e.g., agents targeting activin signaling). These are being studied for sarcopenia and may eventually offer pharmacologic muscle preservation options alongside GLP-1s, but they’re not yet ready for routine clinical use.

Who Might Consider GLP‑1 + TRT—and Who Shouldn’t

Men who might benefit:

Those with obesity-related, symptomatic hypogonadism confirmed by repeat morning testosterone testing and appropriate workup.
Patients already using GLP-1RAs who achieve meaningful fat loss but continue to have hypogonadal symptoms and low testosterone due to functional causes.
Men who value fertility preservation may lean toward starting with GLP-1–led weight loss because gonadotropins remain intact; TRT can be deferred, combined with fertility-preserving strategies, or avoided depending on goals.

Men who may not be good candidates:

Those without confirmed hypogonadism—TRT should not be used solely for weight loss, wellness, or physique.
Individuals with uncontrolled cardiovascular disease, significant erythrocytosis, or prostate cancer concerns, where TRT risk may outweigh benefit.
Older adults with multimorbidity, chronic kidney disease, or complex cardiovascular histories—decisions here require extra caution and specialist input.

Evidence Gaps and What to Watch Next

Combination trials: We still need randomized studies testing GLP-1 + TRT versus either alone for lean mass, strength, metabolic, vascular, and quality-of-life outcomes.
Long-term sarcopenia risk: Does the lean mass proportion lost on GLP-1s translate to functional decline years later?
Imaging and function first: Moving beyond DXA to MRI and standardized performance metrics will clarify whether we’re seeing true muscle loss or healthier remodeling.
High-risk subgroups: Safety and efficacy data in older men, those with diabetes, CKD, or established cardiovascular disease remain limited.
Mechanisms: Clarifying how GLP-1 signaling intersects with testicular function could guide individualized therapy.

What This Means for Patients and Clinics

For many men with obesity, a “weight-first” approach using GLP-1RAs plus structured training and adequate protein can reduce fat mass while supporting muscle quality and strength.
In men with documented functional hypogonadism, thoughtfully adding TRT may enhance symptom relief and lean mass while GLP-1s carry the metabolic load. Safety screening and ongoing monitoring are non-negotiable.
The combined GLP-1 + TRT strategy is promising—but still evolving. Partner with a clinician who understands both sides of the hormone–metabolism equation.

Conclusion

GLP-1 therapies deliver substantial cardiometabolic benefits, and some proportional lean mass loss is a normal part of effective weight reduction. For select men with confirmed, functional hypogonadism, combining GLP-1RAs with TRT may help preserve muscle and improve quality of life—while GLP-1s simultaneously enhance metabolic and vascular health. The cardiovascular safety profile of TRT looks more reassuring than it once did, but FDA cautions remain, and the right choice still depends on the individual. Until combination-trial data arrive, anchor any plan in resistance training, adequate protein, and careful risk–benefit discussion with your care team.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making decisions about medications, hormones, or lifestyle changes.

GLP-1 plus TRT to Preserve Muscle in Men with Obesity